TREM2 gene expression associations with Alzheimer’s disease neuropathology are region-specific: implications for cortical versus subcortical microglia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Previous post-mortem assessments of TREM2 expression and its association with brain pathologies have been limited by sample size. This study sought to correlate region-specific TREM2 mRNA expression with diverse neuropathological measures at autopsy using a large sample size (N = 945) of bulk RNA sequencing data from the Religious Orders Study and Rush Memory and Aging Project (ROS/MAP). TREM2 gene expression of the dorsolateral prefrontal cortex, posterior cingulate cortex, and caudate nucleus was assessed with respect to core pathology of Alzheimer’s disease (amyloid-β, and tau), cerebrovascular pathology (cerebral infarcts, arteriolosclerosis, atherosclerosis, and cerebral amyloid angiopathy), microglial activation (proportion of activated microglia), and cognitive performance. We found that cortical TREM2 levels were positively related to AD diagnosis, cognitive decline, and amyloid-β neuropathology but were not related to the proportion of activated microglia. In contrast, caudate TREM2 levels were not related to AD pathology, cognition, or diagnosis, but were positively related to the proportion of activated microglia in the same region. Diagnosis-stratified results revealed caudate TREM2 levels were inversely related to AD neuropathology and positively related to microglial activation and longitudinal cognitive performance in AD cases. These results highlight the notable changes in TREM2 transcript abundance in AD and suggest that its pathological associations are brain-region-dependent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · cited 1×
“For example, Aβ plaque deposits more abundantly in the cortex of AD patients [47] and previous studies have shown microglial metabolism may become inefficient or fail given a high amyloid burden [3] which paves the possibility that the lack of association in this region may be due to loss of function.”
BackgroundSingle-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Self-citationNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“Braak staging of neurofibrillary tangle distribution and severity along with complimentary measures of neuritic plaque abundance by Consortium to Establish a Registry for Alzheimer’s disease (CERAD) scoring and spatial–temporal Aβ deposition capturing both neuritic and diffuse plaque progression by Thal phasing were a…”
MethodSelf-citationSpatial and temporal heterogeneity of mouse and human microglia at single-cell resolution
Masuda, T., Sankowski, R., Staszewski, O., Böttcher, C., Amann, L., Sagar, Scheiwe, C., Nessler, S., Kunz, P., van Loo, G., et al. (2019) · Nature · doi:10.1038/s41586-019-0924-x · Cited by 1,310 · cited 1×
“Evidence from transcriptomic- and other omic-profiling has revealed distinctive spatial and molecular patterns of microglia across the brain [32, 37, 52].”
BackgroundTREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263 · cited 1×
“This is particularly intriguing given the recent links between microglial metabolic fitness, glucose metabolism, and TREM2 function [33, 55].”
BackgroundSelf-citationReligious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260 · cited 4×
“A clinical diagnosis was made at each participant visit based on the combination of cognitive tests scores, clinical judgement by a neuropsychologist, and diagnostic classification by a clinician (neurologist, geriatrician, or geriatric nurse practitioner) as previously described [6, 8, 9].”
MethodInfluentialSelf-citationMassively parallel single-nucleus RNA-seq with DroNc-seq
Habib, N., Avraham-Davidi, I., Basu, A., Burks, T., Shekhar, K., Hofree, M., Choudhury, S. R., Aguet, F., Gelfand, E., Ardlie, K., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4407 · Cited by 1,069
A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease
Baik, S. H., Kang, S., Lee, W., Choi, H., Chung, S., Kim, J.-I., & Mook-Jung, I. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.005 · Cited by 843
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 1×
“This observation supports the most characterized role of TREM2 in microglia regulating pathological Aβ development [34, 57, 64, 65].”
TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function
Zhao, Y., Wu, X., Li, X., Jiang, L.-L., Gui, X., Liu, Y., Sun, Y., Zhu, B., Piña-Crespo, J. C., Zhang, M., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.031 · Cited by 763
Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200785 · Cited by 549
Leyns, C. E. G., Ulrich, J. D., Finn, M. B., Stewart, F. R., Koscal, L. J., Remolina Serrano, J., Robinson, G. O., Anderson, E., Colonna, M., & Holtzman, D. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710311114 · Cited by 517 · cited 1×
“Rather, it is thought to be the case that TREM2 regulation of microglial activity and subsequent immune dysfunction are external triggers of neuronal tau pathology via microgliosis and excessive neuroinflammation [35].”
BackgroundMicroglial activation and tau propagate jointly across Braak stages
Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490
In vivo staging of regional amyloid deposition
Grothe, M. J., Barthel, H., Sepulcre, J., Dyrba, M., Sabri, O., Teipel, S. J., Initiative, F. T. A. D. N., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004643 · Cited by 440 · cited 1×
“The CN is also a region shown to be vulnerable to amyloid pathology, albeit a subcortical region thought to be affected later-on in the spatial–temporal pattern of plaque progression in AD as compared to neocortical regions [23].”
BackgroundRibosome Dysfunction Is an Early Event in Alzheimer's Disease
Ding, Q., Markesbery, W. R., Chen, Q., Li, F., & Keller, J. N. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3040-05.2005 · Cited by 433
TREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W. W., Hatanpaa, K. J., Lomen-Hoerth, C., Kertesz, A., Bigio, E. H., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-19 · Cited by 404
Microinfarct Pathology, Dementia, and Cognitive Systems
Arvanitakis, Z., Leurgans, S. E., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2011) · Stroke · doi:10.1161/strokeaha.110.595082 · Cited by 404
Self-citationZhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371 · cited 1×
“This observation supports the most characterized role of TREM2 in microglia regulating pathological Aβ development [34, 57, 64, 65].”
Initiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347 · cited 1×
“Therefore, transcriptional upregulation of TREM2 mRNA expression may be closer coupled to levels of amyloid rather than tau pathology in earlier affected cortical regions; this is despite concurrent elevations in its soluble protein fragment and phosphorylated tau in CSF described in MCI and early AD [27, 51].”
BackgroundElucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303 · cited 1×
“Therefore, transcriptional upregulation of TREM2 mRNA expression may be closer coupled to levels of amyloid rather than tau pathology in earlier affected cortical regions; this is despite concurrent elevations in its soluble protein fragment and phosphorylated tau in CSF described in MCI and early AD [27, 51].”
BackgroundDavies, D. S., Ma, J., Jegathees, T., & Goldsbury, C. (2017) · Brain Pathology · doi:10.1111/bpa.12456 · Cited by 251
TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247 · cited 3×
“Furthermore, in APP23 transgenic mice, microglia surrounding Aβ increased expression of TREM2 corresponding with the progression of amyloid pathology [21].”
BackgroundInfluentialTREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice
Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · cited 1×
“TREM2 signaling has been tied to mechanisms of phenotypic switching of microglia, regulation of neuropathology, and cognition [29, 30, 63].”
BackgroundFelsky, D., Roostaei, T., Nho, K., Risacher, S. L., Bradshaw, E. M., Petyuk, V., Schneider, J. A., Saykin, A., Bennett, D. A., & De Jager, P. L. (2019) · Nature Communications · doi:10.1038/s41467-018-08279-3 · Cited by 169
Self-citationA Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease
Serrano-Pozo, A., Gómez-Isla, T., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.02.031 · Cited by 169 · cited 1×
“This increase in glial activation in disease is thought to include a reduction of microglial cell arborization without a reduction in total microglial cell density [48].”
BackgroundLue, L., Schmitz, C. T., Serrano, G., Sue, L. I., Beach, T. G., & Walker, D. G. (2015) · Brain Pathology · doi:10.1111/bpa.12190 · Cited by 154
Cerebrovascular Disease Pathology and Parkinsonian Signs in Old Age
Buchman, A. S., Leurgans, S. E., Nag, S., Bennett, D. A., & Schneider, J. A. (2011) · Stroke · doi:10.1161/strokeaha.111.623462 · Cited by 133
Self-citationJiang, T., Tan, L., Zhu, X.-C., Zhou, J.-S., Cao, L., Tan, M.-S., Wang, H.-F., Chen, Q., Zhang, Y.-D., & Yu, J.-T. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.019 · Cited by 111 · cited 1×
“TREM2 signaling has been tied to mechanisms of phenotypic switching of microglia, regulation of neuropathology, and cognition [29, 30, 63].”
BackgroundBeach, T. G., Sue, L. I., Walker, D. G., Sabbagh, M. N., Serrano, G., Dugger, B. N., Mariner, M., Yantos, K., Henry-Watson, J., Chiarolanza, G., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111340 · Cited by 74
Selected Findings from the Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Wilson, R. S., Arvanitakis, Z., Boyle, P. A., de Toledo-Morrell, L., & Schneider, J. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129007 · Cited by 69 · cited 3×
“A clinical diagnosis was made at each participant visit based on the combination of cognitive tests scores, clinical judgement by a neuropsychologist, and diagnostic classification by a clinician (neurologist, geriatrician, or geriatric nurse practitioner) as previously described [6, 8, 9].”
MethodSelf-citationAPOE ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults
Oveisgharan, S., Buchman, A. S., Yu, L., Farfel, J., Hachinski, V., Gaiteri, C., De Jager, P. L., Schneider, J. A., & Bennett, D. A. (2018) · Neurology · doi:10.1212/wnl.0000000000005677 · Cited by 62
Self-citation
Cited by
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Brain macrophage development, diversity and dysregulation in health and disease
Silvin, A., Qian, J., & Ginhoux, F. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01053-6 · Cited by 137
The role of TREM2 in Alzheimer’s disease: from the perspective of Tau
Huang, W., Huang, J., Huang, N., & Luo, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1280257 · Cited by 49
Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer’s disease
Phillips, J. M., Winfree, R. L., Seto, M., Schneider, J. A., Bennett, D. A., Dumitrescu, L. C., & Hohman, T. J. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02828-5 · Cited by 25
Self-citationWang, T., Liu, X., Wang, X., Hua, F., & Yan, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739875 · Cited by 14
Metadata
- Authors
- Winfree, R. L., Seto, M., Dumitrescu, L., Menon, V., De Jager, P., Wang, Y., Schneider, J., Bennett, D. A., Jefferson, A. L., & Hohman, T. J.
- Venue
- Acta Neuropathologica
- Published
- 2023-03-25
- Volume
- 145
- Issue
- 6
- Pages
- 733-747
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W4360946247
- Cited by
- 40
- References
- 34
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.